Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847201 | 0.98 | ALDH1A1 (0.71) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7378757 | 0.98 | ALDH1A1 (0.71) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL4161467 | 0.94 | ALDH1A1 (0.77) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL8372730 | 0.92 | ALDH1A1 (0.87) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL1888128 | 0.90 | ALDH1A1 (0.77) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7656765 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL13305834 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL21828406 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL5805320 | 0.88 | ALDH1A1 (0.87) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7928970 | 0.86 | ALDH1A1 (0.77) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436939-B2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING SLEEP/WAKE DISORDERS, DEMENTIA, ALZHEIMER'S DISEASE, EPILEPSY, NARCOLEPSY, EATING DISORDERS, MOTION SICKNESS, VERTIGO | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-20 | — | — | US | disclosed |
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074810-A2 | METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-4861897-A | 2-Aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | HRH3, HRH4, HRH2 | ALDH1A1 1270/4885HPGD 1723/4885HTT 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.